Therefore, it is important to design prospective studies that examine CD74 and MIF as biomarkers of ICB response or irAE development across a broad range of cancers, irAEs, and ICB treatments to determine their generalizable use in human subjects [3]. This evidence concerns the gene CD74 and cancer.